Sep 2026· Journal of Microbiology· 0 citations· 52 references
Medicine
Abstract
The convergence of synthetic biology and artificial intelligence is widening the gap between technological advancement and existing regulatory frameworks - a phenomenon known as regulatory lag. As global competition intensifies to capture a synthetic biology market projected to reach approximately $70 billion by 2030, nations are responding to this challenge through markedly different approaches. This study applies a comparative legal methodology, drawing on co-evolutionary theory and the Law 1.0/2.0/3.0 framework, to analyze the regulatory responses of the United States, United Kingdom, Japan, and South Korea. The analysis reveals that national differences stem less from institutional design choices than from the triggers that initiate regulatory change, yielding four distinct co-evolutionary pathways. In the United States, a shift in the judicial environment prompted regulatory adaptation; in the United Kingdom, a political transition created the conditions for legislative reform; and in Japan, administrative reinterpretation of existing rules enabled regulatory adjustment. South Korea represents a fundamentally different case. By enacting the world's first standalone synthetic biology legislation prior to full technological maturation, Korea has pursued a top-down co-evolutionary model in which institutional design precedes and shapes the trajectory of technological development. Three conclusions emerge from this analysis: there is no single optimal co-evolutionary pathway; institutional flexibility determines the sustainability of co-evolution; and co-evolution can itself be an object of proactive design. For Korea's preemptive model to prove effective, it requires a sufficient scientific foundation, institutional flexibility, and coherence with existing regulatory frameworks - conditions that offer a reference point for other nations confronting similar governance challenges.
This Perspective examines the trajectory of Spain's synthetic biology community, highlighting foundational contributions, current strengths and emerging opportunities, and the need to balance engineering ambition with biological complexity, innovation with deployability and control with emergence.
Germán Rivas, Irene Otero-Muras, V. de Lorenzo· Engineering Biology· 0 citations
Evolutionary developmental biology (evo-devo) and evolutionary biochemistry share a common goal: to understand the causes of phenotypic evolution in terms of the mechanisms that translate genetic sequence information into developmental outcomes or the structure/function of macromolecules. Although dialog between the tw...
S. Herrera-Álvarez, Joseph W. Thornton· Annual Review of Ecology, Ev...· 0 citations
Snake venom represents a striking example of evolutionary innovation, in which ancestral physiological gene networks have been co-opted into potent biochemical weapons. Advances in multi-omics, single-cell genomics, and structural bioinformatics have catalyzed a conceptual shift from descriptive toxin cataloging to a s...
I. Ajeh, Ozhe Sunday Isaac Ikukpla’si· Toxicon· 0 citations
The Regulation on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies, which entered into force in 2026, is interpreted, with a particular focus on its new dual-track regulatory framework that comprises a drug registration pathway and a new biomedical technology...
Wei Li, Zhen Qin, Xiu'e Wang et al.· Cytotherapy and Longevity· 0 citations
Canada was one of the first countries to adopt agricultural biotechnology products. This has served Canada well as it is constantly ranked among the world’s top agriculture commodities exporters with its products reaching markets in all continents. However, the speed at which regulations enabling the commercialization...
L. Luque, J. Hubert· Frontiers in Bioengineering...· 0 citations
The presented international experience can establish a foundation for an effective response to the main challenges hindering biotechnology development in Russia, however, achieving maximum efficacy will require adaptation of these tools to the specific economic and legal realities of the Russian Federation.
A. Kanev, N. Kurakova, O. Eremchenko· I P Pavlov Russian Medical B...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.